To compare respiratory compliance and functional residual capacity in infants randomized to a rescue course of antenatal steroids vs placebo.
R
espiratory distress syndrome (RDS) is a common complication of preterm delivery and increases neonatal mortality and morbidity. 1 A single course of antenatal steroids (AS) remains the standard of care for women at risk for preterm delivery between 24 and 34 weeks of gestation, 2, 3 and significantly decreases mortality and RDS. The optimal response to a course of AS occurs if it is given at least 24 hours before but within 7 days of delivery. 2, 3 The duration of the clinical effect of a course of AS remains uncertain, and the efficacy and safety of repeat courses of AS remains a topic of continuing debate and study. [4] [5] [6] [7] Recent randomized data show weekly courses of AS in preterm infants may improve lung function outcomes. 5, 6 Crowther et al randomized 982 women at Ͻ32 weeks of gestation to weekly AS vs placebo. 5 They demonstrated a significant decrease in RDS and severe lung disease in the AS group. 5 The Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal Fetal Medicine Units Network also reported improved pulmonary outcomes in preterm infants randomized to weekly courses of AS vs placebo. 6 Despite the suggestion of pulmonary benefits after repeat courses of AS, concern remains of possible harm after weekly AS therapy, particularly in terms of reduced in utero growth and long-term neurodevelopmental outcome. 7 However, a recent trial by Garite et al of 1 rescue course of AS vs placebo showed improved neonatal outcome without apparent increased short-term risk.
We have used measurements of pulmonary function, specifically passive respiratory compliance (Crs) and functional residual capacity (FRC), as an objective and reproducible way of quantifying the effects of AS on pulmonary function. [9] [10] [11] These physiologic measurements correlate with clinical respiratory outcomes. 9, 12 We recently reported that infants Յ32 weeks of gestation treated with a single course of AS Ͼ7 days before delivery had a significantly lower Crs compared with matched infants treated with a course of AS 1-7 days before delivery. 12 The difference in Crs was more striking if the infants received AS Ͼ14 days before delivery. 12 Our objective was to compare pulmonary function (Crs and FRC) in infants who received a course of AS, remained undelivered for at least 14 days, and were randomized to a single rescue course of AS vs placebo. We hypothesized that infants who received a rescue course of AS would have a significantly increased Crs compared with those who received placebo.
MATERIALS AND METHODS

Eligibility criteria
This prospective randomized trial was conducted at the Neonatal Intensive Care Unit at Oregon Health and Science University (Portland, OR) and at Sacred Heart Hospital (Pensacola, FL). The study was approved by the institutional review boards at each institution and informed consent obtained for each enrolled patient. This study is registered with clinicaltrials.gov (registration no. NCT00669383). Inclusion criteria included: (1) pregnant women 26 to Ͻ34 weeks of gestation; (2) at least 14 days after first course of AS (93% received betamethasone); (3) continued risk of preterm delivery as determined by their care provider; and (4) informed consent.
We excluded patients with: (1) multiple gestations greater than twins; (2) insulin dependent diabetes; (3) clinical chorioamnionitis; (4) major documented fetal or chromosomal abnormalities; (5) first course of AS given at Ͻ24 weeks of gestation; and (6) chronic steroid use during pregnancy for clinical care.
Study design
This was a prospective, randomized, double-blinded trial stratified by gestational age (Յ28 vs Ͼ28 weeks' gestation) and multiple gestation (twins vs singletons). After obtaining informed consent, patients were randomized to rescue AS or placebo only if there were recurrent signs of preterm delivery as determined by the mother's clinician. Patients assigned to the "rescue AS" group received a course of AS (two 12 mg intramuscular injections of betamethasone [Celestone Soluspan; Schering-Plough Corporation, Kenilworth, NJ] 24 hours apart). Those assigned to the "placebo" group received 2 doses of placebo that were identical in appearance to the betamethasone and consisted of 25 mg cortisone acetate, an inactive steroid. 10 Group assignment was performed using a randomization table. A staff pharmacist performed randomization and study drug preparation at each institution, and all patients, investigators, and care providers were unaware of treatment allocation. Pulmonary function was measured within 72 hours of birth and before surfactant therapy, when required. Infants were studied in the supine position while quietly asleep; no sedation was used.
Comparisons of Crs and FRC between groups were our primary endpoints. Other pertinent clinical outcome measures between groups were also monitored. All outcomes were assessed blinded to treatment group allocation.
Measurements
Respiratory mechanics and lung volume were measured with a computerized infant pulmonary function cart (SensorMedics 2600; SensorMedics Inc, Yorba Linda, CA). Crs was obtained with the single-breath occlusion technique and FRC with the nitrogen washout method. [9] [10] [11] [12] In intubated patients, including those requiring surfactant, testing was performed by connecting the infant's endotracheal tube into the system via a 3-way valve that also connected to the ventilator. In nonintubated patients, a face mask was used. [9] [10] [11] For the single-breath occlusion technique, 9 ,12-15 the airway was briefly occluded at end inspiration until an airway pressure plateau was observed and the Hering Breuer reflex invoked. The linear portion of the passive flow-volume curve was identified, and a regression line drawn to obtain the best fit. From the intercepts on the flow and volume axes, respiratory system compliance and resistance were calculated. Acceptance criteria included: (1) stable end expiratory baseline; (2) plateau pressure lasting Ͼ100 msec; (3) plateau pressure varying by Ͻ Ϯ 0.125 cm H 2 O; (4) acceptable flow-volume curve by visual inspection, with linear data segment identified; and (5) at least 10 breaths accepted with a coefficient of variation of Ͻ20%.
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For the nitrogen washout technique, [9] [10] [11] 17, 18 calibration was performed with 2 known volumes, and a calibration line was constructed for the system at the specific flow rate. The calibration curve was then used to correlate the nitrogen washed out to the infant's FRC. The system corrected for dead space present and corrected the FRC to body temperature, pressure, and water-saturated conditions. Total FRC was related to body weight. Acceptance criteria included: (1) infant supine and quietly asleep; (2) test initiated at end expiration; (3) no evidence of leak on tracing of the washout; (4) consistent tracings; and (5) at least 3 measurements with a coefficient of variation of Ͻ10%.
Growth measurements (weight, head circumference, and length) at birth and hospital discharge were compared between groups, and corresponding Z-scores for these measurements were calculated. 19, 20 Other clinical outcome parameters, including surfactant administration, diagnosis of RDS (defined as clinical signs of respiratory distress with radiographic appearance and needing supplemental oxygen with FiO 2 Ͼ0.21), respiratory distress with FiO 2 requirement Ն0.30 and Ն0.40 at 24 hours of age, days on mechanical ventilation, and days on supplemental oxygen were monitored. The statistical analyses were on intention-to-treat. Comparisons of the primary outcomes between groups were performed using linear mixed modeling. 21, 22 This approach accounts for the correlation (nonindependence) between twins, and allows for adjustment of additional covariates and potential confounders. 21, 22 We began with a model, including rescue dose, gestational age (GA) at birth, multiple gestations, maternal smoking history, rupture of mem- Power calculations were based on previous studies. We reported a 50% increase in Crs in preterm infants treated with a single course of AS 1-7 days before delivery when compared with matched untreated infants. 9 We also conducted a randomized trial, in which infants undelivered 1 week after their initial AS course were randomized to weekly AS versus placebo. 10 Infants randomized to placebo delivered an average of 24 days after AS dosing and had Crs measurements that were on average 20% lower than in infants randomized to weekly AS. These findings were not significantly different perhaps due to small sample size, as the study was stopped early due to concerns of possible adverse effects of weekly AS therapy.
Statistical methods
Differences in continuous variables
For our current study, we hypothesized that infants in the rescue AS group would have significantly increased Crs than those in the placebo group. We estimated that to show about a 30% difference in Crs between the groups, we would need to study approximately 40 pregnancies in each group to reject the null hypothesis with a type I error of 0.05 and a power of 80%. Data were reviewed once by the independent, data safety monitoring committee, who were not aware of treatment-group allocation. An interim analysis was conducted when 49.6% (56/113) of the infants were delivered.
RESULTS
Patients were recruited from June 2001 to May 2007. The study profile is shown in the Figure. A total of 44 mothers with 56 infants were randomly assigned to a rescue course of AS and 41 mothers with 57 infants to placebo. The first 8 patients were recruited at Sacred Heart Hospital, with the remaining patients recruited at Oregon Health and Science University. Eighty-six percent of the rescue and 90% of the placebo group received a full course of the study medication. Neonatal data were not available for 1 infant in the placebo group, resulting in 56 vs 56 infants available for analysis ( Figure) .
Maternal and infant characteristics were comparable between the groups (Tables 1 and 2 ), except for significantly more smokers by history in the rescue group. Both groups of mothers received Preeclampsia, n (%) 3 (7) 2 (5) (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) days in the placebo group (median, 25th-75th percentiles; P ϭ .66). Eighty-three of a total of 113 infants (73.5%) were delivered at Յ34 weeks. There were no significant differences in birthweight, GA at birth, admission head circumference, birth length, or incidence of small for GA infants (birthweight Ͻ10th percentile) between groups. There was no difference in Z-scores for birthweight, head circumference, or length between groups ( Table 2) . Pulmonary function tests were performed at a median postnatal age of 22 hours in the rescue AS and 21 hours in the placebo group. Successful measurements of Crs were obtained in 49 rescue and 49 placebo patients. Accounting for the correlation between twins and using linear mixed modeling, there was a significant difference in Crs with the rescue AS group having a mean Crs of 1.21 mL/cm H 2 O/kg vs 1.01 mL/cm H 2 O/kg in the placebo group, adjusted 95% confidence interval (CI) for difference (0.01-0.49), P ϭ .0433 (Table 3) . We did not demonstrate a significant difference in FRC between groups: 24.8 mL/kg in the rescue vs 22.0 mL/kg in the placebo group, adjusted 95% CI for difference (Ϫ1.40 to 6.62), P ϭ .19 (Table 3) .
Although not 1 of the primary outcome variables of our study, fewer patients in the rescue group required surfactant or had RDS compared with the placebo group, but this was not significantly different. However, significantly fewer patients in the rescue group required Ն30% oxygen (13% vs 29%) or Ն40% oxygen (9% vs 23%) than those in the placebo group (P Ͻ .05; Table 4 ). There was no significant difference in discharge weight, head circumference, or length; or in Z-scores for these growth measurements between groups (Table  4) . From the total study population, there was 1 neonatal death caused by sepsis in the rescue group.
In the planned subgroup analysis of infants born at Յ34 weeks (44 rescue and 39 placebo patients), there were no significant differences in growth measurements or corresponding Z-scores at birth (Table 5 ). This subgroup demonstrated more pronounced pulmonary benefits: Crs in the rescue group was 1.17 mL/cm H 2 O/kg vs 0.90 mL/cm H 2 O/kg in the placebo group, adjusted 95% CI for difference (0.02-0.60), P ϭ .0395. There was no significant difference in FRC measurements (Table 3) . Fewer patients in the rescue group had any RDS, required Ն30% oxygen, or Ն40% oxygen than patients in the placebo group (P Ͻ .05), suggesting an enhanced benefit of rescue AS in those at highest risk for respiratory distress. There were no significant differences in discharge growth measurements or corresponding Z-scores (Table 6) . Results using linear mixed models for multivariable modeling are shown in Tables 7 and 8. For the entire study population, when adding GA at first AS therapy, GA at study dosing, race, gender, or mode of delivery to the model, the relationship between rescue AS dose and Crs was relatively unaffected. In addition, none of these variables were statistically significant (Table 7) . Similarly, when adding these 5 covariates to the model, the relationship between rescue dose and FRC was relatively unaffected. For the subgroup of patients who were delivered at Յ34 weeks of gestation, when adding the same 5 covariates to the model, the relationship between rescue dose and Crs (Table 8) or rescue dose and FRC was also relatively unaffected.
COMMENT
Infants randomly assigned to a rescue course of AS have a significantly increased respiratory compliance (about a 20% increase) than patients randomly assigned to placebo. The subgroup of infants who delivered at Յ34 weeks of gestation demonstrates greater pulmonary function benefits (about 30% increase in Crs). Our findings suggest that improvement in Crs translates into improved clinical respiratory outcomes, with less oxygen requirements, and a trend toward less RDS.
Although our study was a randomized, double-blind, placebo-controlled trial, we acknowledge some limitations. Preterm delivery is difficult to predict and therefore treatment with a rescue course of AS may be difficult to time. However, 73.5% of our patients delivered at Յ34 weeks and about 90% received the full course of study medication. Our study was powered to detect differences in pulmonary function tests (Crs), thus assessment of other clinical outcomes will need a larger sample size. Maternal and delivery factors can stimulate endogenous steroid secretion and impact the measurement of newborn pulmonary function. We limited potential confounding factors by using a randomized, placebo-controlled study design. All outcomes were assessed blinded to treatment group assignment, eliminating any possibility of expectation bias. Also, our pulmonary function findings were adjusted for correlation between twins and possible confounding by GA at birth, multiple gestations, maternal smoking, rupture of membranes, and gestational diabetes. 21, 22 Finally, our patients were about 32 weeks of gestation at birth; therefore, our findings may not apply to 
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Obstetrics Research an exclusive population of infants delivered at Ͻ28 weeks. Our findings are consistent with our previous study, demonstrating that infants Յ32 weeks of gestation treated with a single course of AS 1-7 days before delivery had improved Crs compared with infants treated Ͼ7 days before delivery. 12 Our findings of increased Crs in the rescue AS group also are consistent with a multicenter study, 5 reporting a decrease in RDS and severe lung disease in patients randomly assigned to weekly AS vs placebo. This suggests that the enzyme system responsible for surfactant production can be repetitively induced, despite prior treatment with AS. Measurements of pulmonary function have been used to quantify the newborn infant's response to different treatments, 12, 15, 23, 24 including surfactant and AS therapy. 12, 15 Studies in humans and animal models demonstrated significant improvements in respiratory compliance and lung volumes after dosing with AS. 9, 12, 25, 26 A single course of AS is 1 of the most effective therapies available to improve the outcome of infants born prematurely, and when given within 1 week of delivery significantly increases Crs and FRC about 50%. 2, 9, 12 This is the context for the significant increase in Crs of 20-30% that we are demonstrating in this study. However, there are insufficient data on the risks and benefits of repeat/weekly courses of AS, 4, 7, 10, 27 and there are no randomized trials examining the effects of a single repeat course of AS on Crs and FRC in preterm infants.
Several large randomized trials of weekly betamethasone vs placebo, 5, 6, 28 have shown repeat courses of AS have pulmonary benefits. Wapner et al 6 reported no difference in the primary outcome (composite morbidity) between groups. In the entire cohort, and particularly in infants Ͻ32 weeks, there was a significant difference in a number of pulmonary outcomes, with the weekly AS group (24 mg betamethasone) requiring less surfactant and less mechanical ventilation. There was no significant difference in birthweight or head circumference overall, but infants receiving Ն4 courses of AS had decreased birthweight. 6 In addition, 2 studies using lower doses of betamethasone after an initial course of AS have reported conflicting results. 5, 29 In a large study, 982 women were randomly assigned to weekly betamethasone (11.4 mg) vs placebo. 5 Repeat doses of AS significantly decreased the primary outcomes of the study (RDS and severe lung disease) compared with placebo. 5 The second study reported no difference in the primary outcome (survival without RDS or severe intraventricular hemorrhage) between patients randomly assigned to a single dose of betamethasone (12 mg) vs placebo. 29 However, 79% of the study population was born within 24 hours of dosing.
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The 2 most recently published studies used different regimens of repeat AS. 8, 30 Murphy et al 30 reported no difference in the primary outcome (composite morbidity and mortality) between 1858 patients receiving multiple courses of AS (24 mg of betamethasone, every 14 days) or placebo, but documented significant decreases in birthweight, length, and head circumference in the repeat AS group. The mean GA at birth were 34.5 and 34.9 weeks, with 35% of pregnancies delivering at 33-36 weeks and 32% at Ն37 weeks. 30 In contrast, Garite et al 8 recently reported the first large study (n ϭ 437) evaluating a single rescue course of AS on neonatal outcome. They documented a significant reduction in the primary outcome, composite neonatal morbidity at Ͻ34 weeks, in patients randomly assigned to a rescue course of AS (24 mg of betamethasone) vs placebo (43.9% vs 63.6%; P ϭ .002). There was also a significant decrease in RDS, ventilator support, and surfactant use in the rescue AS group; but there were no differences in perinatal mortality or other morbidities, birthweight, and head circumference. 8 A reduction of composite morbidity in the rescue group was still observed (32.1% vs 42.6%; P ϭ .034) as well as decreased respiratory morbidities, when all 558 newborns were included, regardless of GA at delivery. In this study, 55% of patients in each group delivered at Ͻ34 weeks and the mean GA at birth was 33.0 weeks for all patients. 8 Our study design of dosing with a rescue course of AS was very similar to the design of the trial by Garite et al. 8 Our findings of improved respiratory compliance in the rescue AS group (about 20% increase in the total population and 30% in patients Յ34 weeks) are consistent with the latter study, and provide a physiologic basis for the improved respiratory outcomes observed after a rescue course of AS in the trial by Garite et al. 8 A recent metaanalysis confirmed the pulmonary benefits of repeat/weekly AS, 31 but concern remains of possible adverse effects. [4] [5] [6] [7] Crowther et al 32 and Wapner et al 33 reported neurodevelopmental and growth outcomes at 24-36 months of age in infants randomly assigned to weekly AS vs placebo. 5, 6 These studies offer some reassurance that limited weekly AS do not significantly increase major adverse neurodevelopmental outcomes or growth delay, 7, 32, 33 although 1 of the studies reported a nonsignificant trend for increased cerebral palsy after weekly AS. 33 Therefore, additional studies of neurodevelopmental performance and growth are warranted. 7 These studies 32, 33 also raise questions about AS dosing and whether higher doses of prenatal corticosteroids (weekly doses of 24 mg vs 11.4 mg) may increase adverse outcomes.
AS therapy accelerates the structural and biochemical maturation of the fetal lung, reducing the incidence of RDS in preterm infants. 2, 3 As described by Caughey and Parer, 34 to maximize the benefits while minimizing fetal exposure to AS, we randomly assigned patients to a single rescue course of AS vs placebo. Although it has been difficult to define the duration of the pulmonary effects of a single course of AS, data from randomized trials, 2,3 our recent prospective cohort study, 12 and a retrospective study evaluating a rescue dose of AS 35 indicate that it may decrease after 7-14 days. We found an increased Crs in infants assigned to the rescue AS group, with greater changes in infants who delivered at Յ34 weeks. In vitro studies with human lung explants have shown that the biochemical effects of AS begin to decrease after 7 days if AS is removed, 36 although the corresponding structural changes persist. We speculate that the lower Crs in the placebo group in our study may reflect the dissipation of the beneficial effects of AS on induction of the surfactant system. FRC was only slightly increased in the rescue AS group, although not significantly different, suggesting that the structural changes after a course of AS persist longer than the biochemical changes. 10, 36 
CONCLUSIONS
Infants randomly assigned to a single rescue course of AS have a significantly increased Crs compared with those randomly assigned to placebo. The subgroup of patients who delivered at Յ34 weeks demonstrates greater pulmonary function benefits. Our findings suggest that improvement in Crs translates into improved clinical respiratory outcomes. Long-term follow-up of our patients is underway. We speculate that if treatment with a course of AS has occurred Ͼ14 days before delivery, a rescue course of AS may decrease pulmonary morbidity. This should be studied in a large placebo-controlled trial of high-risk patients, and risks and benefits, including long-term pulmonary, growth, and neurodevelopmental outcomes should be monitored. The recent study by Garite et al is an important step toward this goal. 8 
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